Medical Advocates
Abacavir (Ziagen)
 
Journal Citations

General Reports                        Perinatal Data Index
 Diagnostics                                Pediatric Data Index
 Safety
 Dosing
 Pharmacokinetics
 Drug/Drug Interactions
 Viral Dynamics
 Resistance
 Adverse Events
 Pharmacogenetics
Pharmacoeconomics
Adolescent/Adult Indications
Abacavir Main Page Main New/Newsworthy    Home Page    
Last Updated:  March 30, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 ABC/3TC/ZDV data are indexed on the Trizivir Web
ABC/Fixed Dose 3TC data are indexed on the Epzicom Web
General Reports  
       
 
Clinical pharmacogenetics implementation consortium guidelines for hla-B genotype and abacavir dosing.
Martin MA, Klein TE, Dong BJ,  et al
Clin Pharmacol Ther. 2012 Apr;91(4):734-8
 Abstract

Enantioselective synthesis of the carbocyclic nucleoside (-)-abacavir.
Boyle GA, Edlin CD, Li Y,  et al
Org Biomol Chem. 2012 Jan 25
Abstract

Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in
coronary endothelial cells.
 Kim C, Gupta SK, Green L, et al
Antivir Ther. 2011;16(8):1335-9.
 Abstract

Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase.
 Baum PD, Sullam PM, Stoddart CA, McCune JM.
AIDS. 2011 Sep 21.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Toward Eradicating HIV Reservoirs in the Brain: Inhibiting P-glycoprotein at the
Blood-Brain Barrier with Prodrug Abacavir Dimers.
 Namanja HA, Emmert D, Davis DA,  et al
 J Am Chem Soc. 2011 Aug 25.
Abstract

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients
switching to abacavir or tenofovir.
Saumoy M, Ordoñez-Llanos J, Martínez E, et al
Antivir Ther. 2011;16(4):459-468.
Abstract

Separation and characterization of forced degradation products of abacavir sulphate by LC-MS/MS.
Rao RN, Vali RM, Ramachandra B, Raju SS.
J Pharm Biomed Anal. 2010 Sep 22
Abstract

Abacavir and didanosine induce the interaction between human leukocytes and
endothelial cells through Mac-1 upregulation.
 De Pablo C, Orden S, Apostolova N, et al 
AIDS. 2010 May 6.
 Abstract

Near-Infrared Investigations of Novel Anti-HIV Tenofovir Liposomes.
 Zidan AS, Spinks C, Fortunak J,  et al  
AAPS J. 2010 Mar 3.
 Abstract

A WEEK-IN REVIEW FEATURED REPORT
Abacavir: pretreatment screening: warning. Encouraging method but uncertainties remain.
[No authors listed]
 Prescrire Int. 2008 Dec;17(98):239.
Abstract

Current trends in screening across ethnicities for hypersensitivity to abacavir.
Rodriguez-Nóvoa S, Soriano V.
 Pharmacogenomics. 2008 Oct;9(10):1531-41.
 Abstract

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to
clinical utility.
 Hughes AR, Spreen WR, Mosteller M, et al 
Pharmacogenomics J. 2008 Mar 11
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in
clinical practice?
 Barber TJ, Marett B, Waldron S, et al 
AIDS. 2007 Aug 20;21(13):1823-1824.
 Abstract
 
Incidence and reasons of premature discontinuation of abacavir: results of a hospital
investigation among 628 patients.
 Foucher N, Pertusa MC, Lahille B, et al 
Med Mal Infect. 2007 Jul 25;
 Abstract
 
Abacavir prodrugs: Microwave-assisted synthesis and their evaluation of anti-HIV activities.
 Sriram D, Yogeeswari P, Myneedu NS, Saraswat V.  
 Bioorg Med Chem Lett. 2006 Feb 1;
Abstract
 
Lack of Antagonism Between Abacavir, Lamivudine, and Tenofovir Against Wild-Type and
Drug-Resistant HIV-1.
 Lanier ER, Hazen R, Ross L, Freeman A, Harvey R.
J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):519-22
 Abstract
 
Application of phosphoramidate pronucleotide technology to abacavir leads to a significant
enhancementof antiviral potency.
 McGuigan C, Harris SA, Daluge SM, et al 
J Med Chem. 2005 May 19;48(10):3504-15
 Abstract
 
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected
subjects.
 King D, Tomkins S, Waters A, et al
J Allergy Clin Immunol. 2005 May;115(5):1081-7.
 Abstract
 
Abacavir Compared to Protease Inhibitors as Part of HAART Regimens for Treatment of HIV
Infection: Patient Satisfaction and Implications for Adherence.
 Jordan J, Cahn P, Goebel F, et al 
AIDS Patient Care STDS. 2005 Jan;19(1):9-18.
 Abstract
 
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or
indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Cahn P, Vibhagool A, Schechter M, Soto-Ramirez L, et al
Curr Med Res Opin. 2004 Jul;20(7):1115-23.
Abstract

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, b
ut not all, populations.
 Hughes AR, Mosteller M, Bansal AT, et al 
Pharmacogenomics. 2004 Mar;5(2):203-11.
 Abstract

Abacavir: a review of its clinical potential in patients with HIV infection. 
Hervey PS, Perry CM.  
Drugs 2000; 60(2): 447-479.
Abstract
 
FULL-TEXT ARTICLE
Cellular restoration in HIV infected persons treated with abacavir and
a protease inhibitor: age inversely predicts naive CD4 cell count increase.
 Lederman M, McKinnis R, Kelleher D,
AIDS. 14(17):2635-2642, December 1, 2000.
 Abstract
Diagnostics/Monitoring/Screening
       
 
Detection of abacavir hypersensitivity by ELISpot method.
 Esser S, Jablonka R, Heinemann FM, Reuter
Inflamm Allergy Drug Targets. 2012 Feb 15
 Abstract

Rapid HCP5 single-nucleotide polymorphism genotyping: A simple allele-specific PCR method
for prediction of hypersensitivity
reaction to Abacavir.
 Galván CA, Elbarcha OC, Fernández EJ,  et al C
lin Chim Acta. 2011 Apr 14.
 Abstract
 
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir
hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
Russo CD, Lisi L, Lofaro A, Di Giambenedetto S,  et al
Pharmacogenomics. 2011 Apr;12(4):567-76.
 Abstract

HLA-B*5701 testing to predict abacavir hypersensitivity.
 Ma JD, Lee KC, Kuo GM.
PLoS Curr. 2010 Dec 7;2:RRN1203.
 Abstract

Hla-b*5701 genetic screening prior to abacavir prescription in georgia.
Dvali N, Chkhartishvili N, Sharvadze L, et al
Georgian Med News. 2010 Dec;(189):16-20
 Abstract

A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.
 Giardina E, Stocchi L, Cuzzola VF,  et al
Electrophoresis. 2010 Oct 5.
Abstract

Development and Validation of a Selective and Rapid LC-MS-MS Method for the Quantification
of Abacavir in Human Plasma.
Yadav M, Gupta A, Singhal P, Shrivastav PS.
 J Chromatogr Sci. 2010;48(8):654-62.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
Nolan D.
Crit Rev Clin Lab Sci. 2009;46(3):153-65.|
 Abstract

Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic
testing in the Swiss HIV Cohort Study.
 Rauch A, Nolan D, Thurnheer C, et al  
Antivir Ther. 2008;13(8):1019-28.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
Park WB, Choe PG, Song KH, et al  
 Clin Infect Dis. 2009 Feb 1;48(3):365-7.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
 Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with
zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
 Dart Trial Team 
Trop Med Int Health. 2008 Jan;13(1):6-16.
 Abstract

Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration
in human plasma by MALDI-TOF/TOF.
 Notari S, Mancone C, Alonzi T, et al
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 16
Abstract
 
Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
 Waters LJ, Mandalia S, Gazzard B, Nelson M. 
AIDS. 2007 Nov 30;21(18):2533-2534.
Abstract
 
External quality assessment of HLA-B*5701 reporting: an international multicentre survey.
 Hammond E, Almeida CA, Mamotte C, et al   
Antivir Ther. 2007;12(7):1027-32.
Abstract
 
HLA-B*5701 clinical testing: early experience in the United States.   
 Faruki H, Heine U, Brown T. et al
 Pharmacogenet Genomics. 2007 Oct;17(10):857-60.
 Abstract
 
A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir
hypersensitivity syndrome.
 Martin AM, Krueger R, Almeida CA, et al
Pharmacogenet Genomics. 2006 May;16(5):353-357.
Abstract
 
Determination of abacavir in human plasma by high-performance liquid chromatography with
ultraviolet detection and the analytical error function.
 Ferrer SM, Modamio P, Lastra CF, Marino EL.
 Biomed Chromatogr. 2004 Sep 6
Abstract
Safety
 
  FULL-TEXT ARTICLE
 Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected
adults
 Saag MS, Sonnerborg A, Torres R, et al
AIDS: Vol 12(16) 12 Nov 1998 p F203-F209
Paper
Dosing
       
 
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
 Martin MA, Klein TE, Dong BJ
Clin Pharmacol Ther. 2012 Feb 29
 Abstract

FULL-TEXT ARTICLE
 Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of
Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir  
 Sadler BM, Gillotin C, Lou Y, Stein DS.
Antimicrob Agents Chemother 2000 Jun;44(6):1655-1659
 Paper

FULL-TEXT ARTICLE
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with
zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S, Katlama C,Harrer T, et al
 AIDS. 12(16):F197-F202, November 12, 1998.
 Paper
Pharmacokinetics   
       
 
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir
or raltegravir in HIV-infected subjects.
 Jackson A, Moyle G, Dickinson L,  et al
Antivir Ther. 2012;17(1):19-24
 Abstract

FULL-TEXT ARTICLE
 Erequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from
northeastern Brazil.
 Crovella S, Biller L, Santos S, et al
Clinics (Sao Paulo). 2011;66(8):1485-8. |
 Paper

Abacavir and Metabolite Pharmacokinetics in HIV-1-Infected Children and Adolescents.
 Cross SJ, Rodman JH, Lindsey JC, et al  
 J Acquir Immune Defic Syndr. 2009 Mar 11
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Steady-State Pharmacokinetics of Plasma Abacavir and Intracellular Carbovir Triphosphate
following Abacavir 600mg Once Daily and 300mg Twice Daily in HIV-Infected Subjects
Moyle G, Boffito M, Fletcher C, et al 
Antimicrob Agents Chemother. 2009 Feb 2.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Abacavir Pharmacokinetics During Chronic Therapy in HIV-1-Infected Adolescents and Young Adults.
 Sleasman J, Robbins B, Cross S, et al 
Clin Pharmacol Ther. 2008 Dec 3
 Abstract
 
Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid.
 Capparelli EV, Letendre SL, Ellis RJ, et al   
 Antimicrob Agents Chemother. 2005 Jun;49(6):2504-6
 Abstract
 
Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.
 Jullien V, Treluyer JM, Chappuy H, et al 
Br J Clin Pharmacol. 2005 Feb;59(2):183-8.
 Abstract

Membrane permeation characteristics of abacavir in human erythrocytes and human
T-lymphoblastoid CD4(+) CEM cells: comparison with (-)-carbovir.
 Mahony WB, Domin BA, Daluge SM, et al 
Biochem Pharmacol. 2004 Nov 1;68(9):1797-805.
 Abstract

 
The metabolic activation of abacavir by human liver cytosol and expressed human alcohol
dehydrogenase isozymes.
Walsh JS, Reese MJ, Thurmond LM.
Chem Biol Interact 2002 Nov 10;142(1-2):135-54
 Abstract
 
FULL-TEXT ARTICLE
Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System.
Drusano GL, Bilello PA, Symonds WT, et al.
Antimicrob Agents Chemother 2002 Feb;46(2):464-470
 Paper
 
Pharmacokinetics of abacavir in hiv-1-infected patients with impaired renal function.
Izzedine H, Launay-Vacher V, Aymard G,
Nephron 2001 Sep;89(1):62-67
 Abstract
 
FULL-TEXT ARTICLE
 Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in
Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults 
McDowell JA, Lou Y, Symonds WS,Stein DS.
Antimicrob. Agents Chemother. 2000 44: 2061-2067
Paper
 
FULL-TEXT ARTICLE
 Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and
Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency
Virus Infection
Wang LH, Chittick GE, McDowell JA.
Antimicrob Agents Chemother 1999 Jul;43(7):1708-1715
Paper
 
FULL-TEXT ARTICLE
 Pharmacokinetics of Abacavir, a Human Immunodeficiency Virus Type1 (HIV-1) Reverse
Transcriptase Inhibitor ,Administered in a Single Oral Dose to HIV-1-Infected Adults: a
Mass Balance Study
McDowell JA, Chittick GE, Ravitch JR, et al
Antimicrob Agents Chemother 1999 Dec;43(12):2855-2861
 Paper

 
 
Drug/Drug Interactions    
       
 
Abacavir and tenofovir disoproxil fumarate co-administration results in a
nonadditive antiviral effect in HIV-1-infected patients.
 Goicoechea M, Jain S, Bi L, et al  
AIDS. 2010 Mar 13;24(5):707-716.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically
treated for opiate addiction.
 Friedland G, Andrews L, Schreibman T, et al
 AIDS. 2005 Oct 14;19(15):1635-1641.
Abstract
 
Pharmacokinetics and Pharmacodynamics of Low Dose Mycophenolate Mofetil in HIV-Infected
Patients Treated with Abacavir, Efavirenz and Nelfinavir.
Millan O, Brunet M, Martorell J, et al
Clin Pharmacokinet. 2005;44(5):525-38.
 Abstract
 
Methadone blood concentrations are decreased by the administration of abacavir plus
amprenavir.
 Bart PA,  Rizzardi PG, Gallant S et al .
Ther Drug Monit 2001 Oct;23(5):553-5
 Abstract
 
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone
and in combination with abacavir in HIV-infected adults with limited antiretroviral
experience.
Schooley RT,Clumeck N, Haubrich R, et al.  
Antivir Ther 2001 Jun;6(2):89-96
Abstract
 
FULL-TEXT ARTICLE
 Pharmacokinetic Interaction of Abacavir (1592U89) and Ethanol in Human Immunodeficiency
Virus-Infected Adults  
 McDowell JA, Chittick GE, Stevens CP, et al.
Antimicrob Agents Chemother 2000 Jun;44(6):1686-1690
 Paper
 
 

Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful
abacavir-based simplified therapy.
 Pellegrin I, Caumont A, Garrigue I,  et al.
J Infect Dis 2003 Jan 1;187(1):38-46
 Abstract

  
Viral Dynamics
       
 
A WEEK-IN-REVIEW-FEATURED REPORT
Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir.
 Bansi L, Sabin C, Gilson R, et al
 J Infect Dis. 2009 Jul 27.
Abstract

Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with
pegylated interferon and weight-adjusted ribavirin.
 Laufer N, Laguno M, Perez I, et al   
Antivir Ther. 2008;13(7):953-7
 Abstract
 
  Viral Dynamics and Their Relations to Baseline Factors and Longer Term Virologic Responses
in Treatment-Naive HIV-1-Infected Patients Receiving Abacavir in Combination with HIV-1
Protease Inhibitors.
 Wu H, Mellors J, Ruan P, et al.
Acquir Immune Defic Syndr. 2003 Aug 15;33(5):557-563.
Abstract
Resistance
       
 
In Vitro HIV-1 Resistance Selections with Combinations of Tenofovir and Emtricitabine or Abacavir
and Lamivudine.
 Margot NA, Waters JM, Miller MD.  
Antimicrob Agents Chemother. 2006 Sep 18;
 Abstract
 
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial
with nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
 
Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro
Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine.
 Stone C, Ait-Khaled M, Craig C, et al   
Antimicrob Agents Chemother. 2004 Apr;48(4):1413-5.
 Abstract

FULL-TEXT ARTICLE
Clinically relevant interpretation of genotype for resistance to abacavir.
 Brun-Vezinet F, Descamps D, Ruffault A, et al  
 AIDS. 2003 Aug 15;17(12):1795-1802
 Paper
 
FULL-TEXT ARTICLE
Prediction of abacavir resistance from genotypic data: impact of Zidovudine and Lamivudine
resistance in vitro and in vivo.
Walter H, Schmidt B, Werwein M, et al.
Antimicrob Agents Chemother 2002 Jan;46(1):89-94
 Paper
 
FULL-TEXT ARTICLE
Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant
to abacavir.
Laethem A, Kristel Van W, MBalzarini J, et al
 AIDS. 14(4):469, March 10, 2000.
 Paper

 
Pharmacogenetics
 
 
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
Martin MA, Klein TE, Dong BJ
Clin Pharmacol Ther. 2012 Feb 29
 Abstract

FULL-TEXT LETTER
 In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.
 Sanchez-Giron F, Carnevale A.
Pharmacogenomics. 2012 Feb;13(3):251-2
 Letter
 
FULL-TEXT LETTER
 Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01 typing for eligibility to abacavir treatment in the Italian population.
 Badulli C, Sestini R, Sbarsi I,  et al
Pharmacogenomics. 2012 Feb;13(3):247-9.
 Letter

Successful translation of pharmacogenetics into the clinic: the abacavir example.
Phillips E, Mallal S.
Mol Diagn Ther. 2009;13(1):1-
 Abstract
Pharmacoeconomics
 
  Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate
in the Treatment of HIV.
Kauf TL, Farkouh RA, Earnshaw SR, et al
Pharmacoeconomics. 2010 Jun 24
 Abstract

Abacavir Main Page Main New/Newsworthy    Home Page    

Abacavir
Journal Papers,  Abstracts, and Commentaries